CJC-1295 vs GHRP-2

Side-by-side comparison of CJC-1295, GHRP-2 — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute CJC-1295 CJC-1295 (Modified GRF 1-29) Growth Hormone GHRP-2 Growth Hormone Releasing Peptide-2 Growth Hormone
Basics
Molecular type GHRH AnalogueGrowth Hormone Releasing Peptide (GHRP)
Amino acids 296
Molecular weight 3,368.9 Da817.9 Da
Half-life 30 min (without DAC) / 7–8 days (with DAC)~1–2 hours
Route(s) Subcutaneous, IntramuscularSubcutaneous, Intramuscular, Intranasal
Mechanism & Research
Primary mechanism CJC-1295 binds GHRH receptors on pituitary somatotroph cells, stimulating GH synthesis and increasing GH pulse amplitude. Unlike native GHRH (half-life <10 minutes), the modified amino acid substitutions in CJC-1295 resi… GHRP-2 activates the ghrelin receptor (GHSR-1a) in the pituitary and hypothalamus. Hypothalamic activation leads to reduced somatostatin tone (the GH release inhibitor), while pituitary activation directly triggers GH se…
Research status Research Compound Research Compound
Evidence summary Phase 1/2 trials with CJC-1295 with DAC confirmed dose-dependent IGF-1 elevation lasting up to 14 days after single injection. CJC-1295 without DAC's pulsatile profile is primarily studied in combination with GHRPs. GHRP-2 has been extensively studied in humans including as a diagnostic tool for GH deficiency assessment. Its well-characterised dose-response relationship makes it a reference compound in the GHRP class.
Protocol & Dosing
Typical dose 100–200 mcg (without DAC); 2mg every 2 weeks (with DAC)100–200 mcg per injection
Frequency 2–3x daily (without DAC); biweekly (with DAC)2–3x daily
Duration 8–16 weeks8–12 weeks
Timing Without DAC: fasted, 2x daily ideally morning + bedtime. With DAC: any time, biweekly.Fasted state; 2+ hours post-meal
Safety
Common side effects
  • Water retention
  • Mild headache
  • Flushing (post-injection)
  • Tingling
  • Cortisol elevation (dose-dependent)
  • Prolactin increase (transient)
  • Increased appetite
  • Water retention
Contraindications
  • Active malignancy
  • Uncontrolled hypothyroidism
  • Pregnancy
  • Active malignancy
  • Hypothyroidism
  • Pregnancy
Anti-doping Prohibited (WADA S2) Prohibited (WADA S2)
Deeper reading
Related peptides Ipamorelin, Sermorelin, GHRP-2, Tesamorelin Ipamorelin, CJC-1295, GHRP-6, Hexarelin
Full profile Read full CJC-1295 profile → Read full GHRP-2 profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.